Genotype analysis of rotaviruses isolated from children during a phase III clinical trial with the hexavalent rotavirus vaccine in China Authors: Wenqi Zou, Qingchuan Yu, Yan Liu, Qingliang Li, Hong Chen, Jiamei Gao, Chen Shi, Ying Wang, Wei Chen, Xuan Bai, Biao Yang, Jiuwei Zhang, Ben Dong, Bo Ruan, Liuyifan Zhou, Gelin Xu, Zhongyu Hu, Xiaoming Yang Published: 2023 ABSTRACT The oral hexavalent live human-bovine reassortant rotavirus vaccine (RV6) developed by Wuhan Institute of Biological Products Co., Ltd (WIBP) has finished a randomized, placebo-controlled phase III clinical trial in four provinces of China in 2021. The trail demonstrated that RV6 has a high vaccine efficacy against the prevalent strains and is safe for use in infants. During the phase III clinical trial (2019–2021), 200 rotavirus-positive fecal samples from children with RV gastroenteritis (RVGE) were further studied. Using reverse transcription-polymerase chain reaction and high-throughput sequencing, VP7 and VP4 sequences were obtained and their genetic characteristics, as well as the differences in antigenic epitopes of VP7, were analyzed in detail. Seven rotavirus genotypes were identified. The predominant rotavirus genotype was G9P [8] (77.0%), followed by prevalent strains G8P [8] (8.0%), G3P [8] (3.5%), G3P [9] (1.5%), G1P [8] (1.0%), G2P [4] (1.0%), and G4P [6] (1.0%). The amino acid sequence identities of G1, G2, G3, G4, G8, and G9 genotypes of isolates compared to the vaccine strains were 98.8%, 98.2%–99.7%, 88.4%–99.4%, 98.2%, 94.2%–100%, and 93.9%–100%, respectively. Notably, the vaccine strains exhibited high similarity in amino acid sequence, with only minor differences in antigenic epitopes compared to the Chinese endemic strains. This supports the potential application of the vaccine in preventing diseases caused by rotaviruses. Introduction Rotavirus (RV) is a major pathogen causing severe gastroenteritis in children under five years of age. RV genome comprises 11 segments of double-stranded RNA, which may generate new variants by reassortants (Gouvea and Brantly, 1995; Tacharoenmuang et al., 2016). In China, the proportion of G9 genotype has been increasing since 2011, of which G9P[8] has gradually become the predominant epidemic strain, while proportions of G1, G2, and G3 genotypes have been decreasing year by year (Geng et al., 2016; Wei et al., 2022; Zhao et al., 2021; Zhang et al., 2022). Given the substantial public health impact of RV diarrheal disease, particularly in low-income countries, the World Health Organization (WHO) recommends two licensed rotavirus vaccines, RotaTeq and Rotarix for universal immunization in 2013 (WHO, 2013). RotaTeq is a reassortant strain of G1–G4 and P [8], whereas Rotarix belongs to the P1A [8] G1 genotype (Soares-Weiser et al., 2019; Bergman et al., 2021), both of which have been prequalified and undergone extensive evaluation in numerous large trials across various continents. In China, Lanzhou lamb rotavirus vaccine (LLR, consisting of rotavirus serotype G10P [12]), manufactured by Lanzhou Institute of Biological Product Co., Ltd, has been licensed in 2000, and RotaTeq received the license at the end of 2018. In April 2023, an oral human-lamb reassortant trivalent vaccine LLR3 (consisting of G2–G4) received marketing approval in China. An oral hexavalent live human-bovine reassortant RV vaccine (RV6) was developed at Wuhan Institute of Biological Products Co., Ltd (WIBP). RV6 is based on the bovine RV strain UK (G6P [5]), reassorted with VP7 gene from human G1, G2, G3, G4, G8, and G9 strains. During the phase I clinical trial in China, RV6 demonstrated excellent tolerance in all adults, young children, and infants (Wu et al., 2021). The randomized, placebo-controlled phase III clinical trial of RV6 was conducted in Hebei, Hunan, Zhejiang Province, and Guangxi Zhuang Autonomous Region from 2019 to 2021. A total of 6400 healthy infants, aged 6–12 weeks, were enrolled and randomly assigned into the RV6 group and placebo group in a 1:1 ratio. The results of the trial showed that RV6 had high vaccine efficacy and safety (Wu et al., 2022). All fecal samples from acute gastroenteritis cases in the phase III clinical trial were collected from the first dose administration until the conclusion of the trial (Wu et al., 2022). Among them, there were 200 RV-positive cases, comprising 145 from the placebo group and 55 from the vaccine group. Reverse transcription–polymerase chain reaction (RT-PCR) has been employed to genotype the RV-positive samples, with 62.5% classified as G genotype and 40.5% as P genotype. RV-positive samples that could not be genotyped by RT-PCR may due to defective RV particles or PCR failure to amplify the VP7 gene (Vesikari et al., 2006). In this study, we further analyzed RV-positive fecal samples from RV6 phase III clinical trial. Fecal samples that could not be genotyped by RT-PCR amplified fragments were subjected to high-throughput sequencing to obtain additional sequences and construct a comprehensive phylogenetic analysis. Materials and methods Samples A total of 200 fecal samples testing positive for RV (RV-positive by the ProSpecT™ enzyme-linked immunosorbent assay kit) were collected from cases of RV gastroenteritis (RVGE) during RV6 phase III clinical trials in Hebei, Hunan, Zhejiang Province, and Guangxi Zhuang Autonomous Region from 2019 to 2021. The abbreviations for the sample names are listed in Supplementary Table S1. Total RNA extraction and amplification of VP7 and VP4 genes Fecal sample (0.1 ​g) was added into 1 ​mL normal saline to prepare 10% suspension of fecal samples, then it was centrifuged at 850 ×g for 5 ​min at 4 ​°C. The supernatant was treated with the QIAamp Viral RNA Mini Kit (Qiagen, USA) to extract RNA. The VP7 and VP4 genes were amplified using the PrimeScript™ One-Step RT-PCR Kit Ver. 2 (TaKaRa, Japan) and Prime-Script™ II High-Fidelity One-Step RT-PCR Kit (TaKaRa, Japan), respectively. The primers for VP7 and VP4 genes are listed in Supplementary Table S2. The RT-PCR for VP7 genes was conducted with an initial RT step at 50 ​°C for 30 ​min, followed by 94 ​°C for 2 ​min, and then 35 cycles of amplification (30 ​s at 94 ​°C, 30 ​s at 55 ​°C, 1 ​min at 72 ​°C), with an extension for 10 ​min at 72 ​°C. The VP4 amplification program was conducted at 45 ​°C for 10 ​min, followed by 94 ​°C for 2 ​min, and then 35 cycles of amplification (at 98 ​°C for 10 ​s, 60 ​°C for 15 ​s, 68 ​°C for 30 ​s), and with a final extension at 72 ​°C for 1 ​min. The VP7 and VP4 genes were sequenced using Sanger sequencing (Sanger et al., 1977). High-throughput sequencing analysis Fecal samples that could not be genotyped by RT-PCR amplified fragments were subjected to high-throughput sequencing using Illumina Hiseq 2500. The raw data were trimmed to remove low-quality sequences and rRNA using Fastp (version 0.23.0) (Chen et al., 2018) and SortMeRNA (version 4.3.6) (Kopylova et al., 2012). The sequences were assembled using SAM tools (version 1.15) and SPAdes (version 3.15.3), and the reference RV A genome was obtained from GenBank (Danecek et al., 2021; Prjibelski et al., 2020). Sequence analysis and genotyping The obtained nucleotide sequences were aligned with reference sequences obtained from the NCBI database using the CLUSTALW multiple alignment tool in MEGAX 10.0. The Virus Pathogen Database and Analysis Resource (VIPR) (https://www.viprbrc.org/brc/rvaGenotyper.spg?method=ShowCleanInputPage&decorator=reo) was used to determine the genotype of VP7 and VP4 (Maes et al., 2009). Analysis of gene phylogenetic trees and acid amino similarity Phylogenetic analyses of genome segments were carried out using MEGAX 10.0. Phylogenetic trees were constructed using the neighbor-joining method with the maximum composite likelihood model. The reliability of the branching order was estimated from 1000 bootstrap replicates. The similarity of different VP7 and VP4 aa sequences was calculated with MegAlign (DNA Star), with only full-length sequences being chosen. The reference sequences of the vaccine strain are shown in Supplementary Table S3, and the reference sequences of strains of each genotype are shown in Supplementary Table S4. Evaluation of VP7 antigenic epitopes of isolates and vaccine strains The antigenic epitopes of VP7 were compared between isolates and vaccine strains for each genotype: 7–1 (7–1a and 7–1b) and 7–2, encompassing a total of 29 antigenic epitopes (Aoki et al., 2009). The VP7 epitopes of six genotype isolates were evaluated in comparison with vaccine strains and reference sequences obtained from the NCBI database. The structural diagrams were constructed using Pymol 3.11. Results Genotyping results of VP7 and VP4 After the unblinding of the phase III clinical trial, ELISA-positive fecal samples were collected to amplify the VP7 and VP4 genes by RT-PCR. Those samples could not be genotyped by RT-PCR amplified fragments were subjected to high-throughput sequencing. Through these two sequencing methods, the VP7 and VP4 encoding genes of 198 isolates out of 200 RV-positive samples were successfully sequenced and typed for G type (encoded by the VP7 gene) and P type (encoded by the VP4 gene), including G1P [8], G2P [4], G3P [8], G3P [9], G4P [6], G8P [8], G9P [8], and mixed genotypes (G2/G9 or P [4]/P [8]) (Fig. 1, Supplementary File). G9 emerged as the predominant genotype in the four provinces, accounting for 94.1% of the identified cases in Hebei Province, 50.0% in Hunan Province, 81.5% in Zhejiang Province, and 70.3% in Guangxi Zhuang Autonomous Region. Among the 198 RV isolates, there were four P types (P [4], P [6], P [8], P [9]), along with one mixed genotype, P [4]/P [8]. The dominant genotype in RV isolates from all four provinces is P [8], accounting for 90.2% in Hebei Province, 94.1% in Hunan Province, 88.9% in Zhejiang Province, and 89.2% in Guangxi Zhuang Autonomous Region. Seven major G/P combinations were observed (Table 1): G2P [4], 1.0% (2/200); G3P [8], 3.5% (7/200); G3P [9], 1.5% (3/200); G4P [6], 1.0% (2/200); G8P [8], 8.0% (16/200); and G9P [8], 77.0% (154/200). Furthermore, seven samples (3.90%) were typed as G9 based on VP7 gene but failed in typing by VP4 gene, and one sample (0.5%) was typed as P [8] based on VP4 gene but failed in typing by VP7 gene. Four samples were found to be mixed infections of G2/G9 and P [4]/P [8], where one sample was G2+P [4]/P [8] (0.5%), one sample was G2/G9+P [8] (0.5%), and two samples were G2/G9+P [4]/P [8] (1.0%).Fig. 1Genotype proportions of rotavirus-positive samples. A Percentage of the G genotype of rotavirus in each province. B Percentage of the P genotype of rotavirus in each province.Fig. 1Table 1Results of G/P typing.Table 1GenotypePlacebo groupRV6 groupTotalG1P[8]202 (1.0%)G2P[4]112 (1.0%)G3P[8]347 (3.5%)G3P[9]303 (1.5%)G4P[6]202 (1.0%)G8P[8]13316 (8.0%)G9P[8]11341154 (77.0%)G9617 (3.5%)P[8]011 (0.5%)G2+P[4]/P[8]011 (0.5%)G2/G9+P[8]011 (0.5%)G2/G9+P[4]/P[8]112 (1.0%)Untyped112 (1.0%)Total14555200 Genotype proportions of rotavirus-positive samples. A Percentage of the G genotype of rotavirus in each province. B Percentage of the P genotype of rotavirus in each province. Table 1Results of G/P typing.Table 1GenotypePlacebo groupRV6 groupTotalG1P[8]202 (1.0%)G2P[4]112 (1.0%)G3P[8]347 (3.5%)G3P[9]303 (1.5%)G4P[6]202 (1.0%)G8P[8]13316 (8.0%)G9P[8]11341154 (77.0%)G9617 (3.5%)P[8]011 (0.5%)G2+P[4]/P[8]011 (0.5%)G2/G9+P[8]011 (0.5%)G2/G9+P[4]/P[8]112 (1.0%)Untyped112 (1.0%)Total14555200 Results of G/P typing. Phylogenetic and sequence analyses Phylogenetic and sequence analyses of the VP7 gene Amino acid (aa) identity and phylogenetic analyses were conducted between isolates and vaccine strains or prevalent strains (Supplementary Table S3). Based on the VP7 gene, the isolates were genotyped as G1–G4, G8, and G9. The aa identity among the G9 isolates was in the range of 93.9%–100.0%, with 90.2%–95.1% aa identity between them and the G9 strain of RV6. The majority of the G9 isolates clustered within lineage VI, closely related to the circulating Chinese strains (with aa identity of 93.9%–100%). Furthermore, three G9 isolates from Zhejiang and Hunan provinces closely clustered with strains from Yunnan and Fujian (93.9%–99.1%) in China within lineage III (Fig. 2). The aa identity among the G8 isolates ranged from 94.2% to 100%, with 90.8%–95.4% between the G8 isolates and the G8 strain of RV6. The G8 isolates clustered closely with strains from Guangzhou (94.2%–100%) and Thailand (93.9%–100%; Fig. 3).Fig. 2Phylogenetic analysis of the VP7 genes of G9 strains. Notes: purple rhombus: vaccine strain; blue circle: isolates from Hebei Province; pink square: isolates from Hunan Province; orange triangle: isolates from Guangxi Zhuang Autonomous Region; green inverted triangle: isolates from Zhejiang Province. Bootstrap values (1,000 replicates) of ≥70% are shown.Fig. 2Fig. 3Phylogenetic analysis of the VP7 genes of G8 strains. Notes: purple rhombus: vaccine strain; pink square: isolates from Hunan Province; orange triangle: isolates from Guangxi Zhuang Autonomous Region; green inverted triangle: isolates from Zhejiang Province. Bootstrap values (1,000 replicates) of ≥70% are shown.Fig. 3 Phylogenetic analysis of the VP7 genes of G9 strains. Notes: purple rhombus: vaccine strain; blue circle: isolates from Hebei Province; pink square: isolates from Hunan Province; orange triangle: isolates from Guangxi Zhuang Autonomous Region; green inverted triangle: isolates from Zhejiang Province. Bootstrap values (1,000 replicates) of ≥70% are shown. Phylogenetic analysis of the VP7 genes of G8 strains. Notes: purple rhombus: vaccine strain; pink square: isolates from Hunan Province; orange triangle: isolates from Guangxi Zhuang Autonomous Region; green inverted triangle: isolates from Zhejiang Province. Bootstrap values (1,000 replicates) of ≥70% are shown. The G3 isolates had an aa identity of 88.4%–99.4%. Specifically, the G3 isolates of lineage IV had an aa identity of 98.5%–99.4%, and G3 isolates of lineage V had an aa identity of 95.4%–99.7% (Fig. 4). The G3 isolates in lineage IV exhibited a higher aa identity (94.5%–95.1%) with G3 strain of RV6 (lineage I) compared to those of lineage V (89.6%–92.4%). The G3 isolates of G3P [8] closely clustered with strains from China (93.3%–96.3%) and Japan (96.6%–100%) in lineage V. Additionally, three G3 isolates of G3P [9] closely clustered with strains from Sichuan Province in China (97.6%–98.2%), Italy, and Russia (99.1%–99.7%) in lineage IV. Furthermore, the G3 isolates had an aa identity of 98.5%–99.1% with the wild-type cat strain.Fig. 4Phylogenetic analysis of the VP7 genes of G3 strains. Notes: purple rhombus: vaccine strain; blue circle: isolates from Hebei Province; pink square: Hunan Province; green inverted triangle: isolates from Zhejiang Province. Bootstrap values (1,000 replicates) of ≥70% are shown.Fig. 4 Phylogenetic analysis of the VP7 genes of G3 strains. Notes: purple rhombus: vaccine strain; blue circle: isolates from Hebei Province; pink square: Hunan Province; green inverted triangle: isolates from Zhejiang Province. Bootstrap values (1,000 replicates) of ≥70% are shown. All the G2 isolates were clustered to lineage IV and formed two clusters with strains from Japan (98.2%–99.7%) and China (95.4%–99.4%). They had an aa identity of 98.2%–99.7% and 95.4%–95.7% with the G2 strain of RV6, which belonged to lineage II (Supplementary Fig. S1). The G1 isolates exhibited a 98.8% aa identity, and had an aa identity of 93.3%–93.9% between isolates and the G1 strain of RV6 (lineage III). The G1 isolates formed a cluster with the Malaysian strain (97.9%–98.2%) in lineage II (Supplementary Fig. S2), and exhibited a 90.8%–92.0% aa identity with strains from Fujian and Hubei provinces in China (lineage I). The two G4 isolates (lineage V) showed a 98.2% aa identity, while exhibited 93.6% and 94.2% aa identity with the G4 strain of RV6 (lineage I). The G4 isolates closely clustered with the Hubei sewage strain (95.4%, 96.0%) and Henan strain (97.9%, 98.5%) in China, as well as the swine strain (98.2%, 99.4%) in Vietnam (Supplementary Fig. S3). Phylogenetic and sequence analyses of the VP4 gene Based on the VP4 gene, there were four genotypes in those isolates (P [4], P [6], P [8], and P [9]). The aa identity among the P [8] isolates ranged from 83.3% to 100%, and they closely clustered with Chinese strains (82.7% to 99.9%), although they originated from different genotype combinations (G9P [8], G8P [8], G3P [8], and G1P [8]) (Fig. 5). The P [4] isolates clustered in lineage V and showed aa identities ranging from 88.9% to 99.5%. Notably, the P [4] isolate from Zhejiang Province shared the same lineage with strains from China and Thailand (Supplementary Fig. S4). The P [9] isolates in lineage I clustered with the Chinese sewage strain (MW254180.1), while the P [9] isolate from Hunan Province was evolutionarily close to the Russian strain (Supplementary Fig. S5). The two P [6] isolates (in lineage II) were evolutionarily close to the wild-type pig strain and the Chinese sewage strain (MW254172.1) (Supplementary Fig. S6).Fig. 5Phylogenetic analysis of the VP7 genes of P[8] strains. Notes: blue circle: isolates from Hebei Province; pink square: Hunan Province; green inverted triangle: isolates from Zhejiang Province; orange triangle: isolates from Guangxi Zhuang Autonomous Region. Bootstrap values (1,000 replicates) of ≥70% are shown.Fig. 5 Phylogenetic analysis of the VP7 genes of P[8] strains. Notes: blue circle: isolates from Hebei Province; pink square: Hunan Province; green inverted triangle: isolates from Zhejiang Province; orange triangle: isolates from Guangxi Zhuang Autonomous Region. Bootstrap values (1,000 replicates) of ≥70% are shown. Comparison of VP7 antigenic epitopes between isolates and the vaccine strain The aa changes may have exerted different selection pressures on these lineages (Rasebotsa et al., 2021). The alignment of the antigenic epitopes among RV6 strain, isolates, and prevalent strains were performed (Fig. 6). Among G1 isolates, there was one aa change (D97E) in 7–1a and one aa change (S147 ​N) in the 7–2 region compared to the G1 vaccine strain (Supplementary Table S5). For G2 isolates, there were four aa changes (A87T, D96 ​N, N125T, and V129 ​M) in 7–1a epitope, and two aa changes (N213D, N242S) in 7–1b epitope compared to the G2 strain of RV6. Notably, these changes remained consistent in Chinese strains over time (Supplementary Table S6). N242S was observed in two isolates (HBZD016 and ZJLY117) and the G2 strain of RV6. Within G3 isolates, there was one aa change (T87S) in the 7–1a region, four aa changes (T212 ​A/V, N213T/D, N238D, and N242A) in the 7–1b region, and one aa change (D145 ​N) in the 7–2 region of VP7 epitopes compared to the G3 strain of RV6. The antigenic epitopes of the G3 strain of RV6 matched those of Chinese G3 strains in lineage VI (Supplementary Table S7). In G4 isolates, there were six aa changes in the antigenic epitopes in the 7–1 region, including S87 ​A/T, T96 ​N, I129V, D211 ​N, A213 ​N, N238D. S94 ​N change in the 7–1a region was found in one isolate from Hebei, and R143K in 7–2 region was found in another isolate from Henan compared to the G4 strain of RV6 (Supplementary Table S8). For G8, there were two aa changes (A87T and A125S) in the 7–1a region, one change (T242 ​N) in the 7–1b region from one isolate, and one change (N145S) in the 7–2 region from two isolates. The observed aa changes on the outer capsids of the G8 isolates and Guangzhou isolates (OK349194.1 & OK349183.1) were consistent (Table 2). The G9 isolates of lineage III showed three joint aa differences at positions 87 (A87T), 242 (T242 ​N), and 221 (S221G). Conversely, G9 isolates of lineage IV contained two aa changes (A87T, D100 ​N) in the 7–1a region, one aa change (T242 ​N) in the 7–1b region, and one aa change (S221G) in the 7–2 region in VP7 epitopes, compared to the G9 strain of RV6. Additionally, one isolate (HNYX156) exhibited an aa change (T147 ​M) in the 7–2 region. Another isolate (ZJYH104) had two aa changes (A87T and T242 ​N). Most of the antigenic epitopes of the predominant G9 strain in China remained stable over time (Table 3).Fig. 6Alignment of the antigenic epitopes of VP7 between RV6 strain and the isolates in China. A Alignment of the antigenic epitopes among RV6 strain, isolates, and prevalent strains. The green markers indicated the antigenic epitopes in VP7 of vaccine strain. The differences between vaccine strains and isolates in VP7 antigenic epitopes were highlighted B Surface representation of the VP7 trimer (PDB 3FMG). Antigenic epitopes are pink (7-1a), cyan (7-1b), and lime green (7-2). The differences of the surface representation of the VP7 trimer between isolates and vaccine strains. Red, the surface-exposed residues that differ between isolates and vaccine strains.Fig. 6Table 2Alignment of the antigenic epitopes of G8 among vaccine strain, isolates, and prevalent strains.Table 2Table 3Alignment of the antigenic epitopes of G9 among vaccine strain, isolates, and prevalent strains.Table 3 Alignment of the antigenic epitopes of VP7 between RV6 strain and the isolates in China. A Alignment of the antigenic epitopes among RV6 strain, isolates, and prevalent strains. The green markers indicated the antigenic epitopes in VP7 of vaccine strain. The differences between vaccine strains and isolates in VP7 antigenic epitopes were highlighted B Surface representation of the VP7 trimer (PDB 3FMG). Antigenic epitopes are pink (7-1a), cyan (7-1b), and lime green (7-2). The differences of the surface representation of the VP7 trimer between isolates and vaccine strains. Red, the surface-exposed residues that differ between isolates and vaccine strains. Table 2Alignment of the antigenic epitopes of G8 among vaccine strain, isolates, and prevalent strains.Table 2 Alignment of the antigenic epitopes of G8 among vaccine strain, isolates, and prevalent strains. Table 3Alignment of the antigenic epitopes of G9 among vaccine strain, isolates, and prevalent strains.Table 3 Alignment of the antigenic epitopes of G9 among vaccine strain, isolates, and prevalent strains. Discussion The circulating rotavirus in the four provinces exhibited phylogenetic diversity, with concurrent detection of the rare Chinese genotypes G3P [9], G4P [6], and G8P [8]. G3P [9] was identified in Hebei, Zhejiang, and Hunan provinces with a detection rate of 1.5%, while G4P [6] was found in both Hebei and Hunan provinces with a 1.0% detection rate. It is plausible that G3P [9] and G4P [6] may be associated with interspecies transmission between humans and animals (Theamboonlers et al., 2013; Grant et al., 2011). Nonetheless, the current identification of G3 and P [6] was also linked to a Chinese sewage strain, underscoring the significance of continuous environmental monitoring. G8P [8] was rarely observed in China until 2021 (Lu et al., 2021). However, there were 16 isolates of G8P [8] from Guangxi, Hunan, and Zhejiang provinces, showed high similarity to the Guangzhou strains. Notably, G8P [8] was also detected in southern China, which may have originated from the prevalent G8P [8] strains in Southeast Asia in recent years (Wang et al., 2022). Another study indicated that G8P [8] was initially identified in Wuhan in December 2021 (Zhou et al., 2023), and subsequently in Beijing (Jiao et al., 2023). This suggests a potential trend of G8P [8] spreading from southern China and becoming increasingly prevalent in Chinese mainland. Therefore, long-term surveillance of G8P [8] is necessary. Our study revealed a high degree of similarity between the G-types of isolates and the vaccine strains of RV6. Most isolates clustered closely with prevalent strains in China and Asia. Despite the vaccine strain originating from a prototype strain several decades ago and prevalent genotypes undergoing continuous evolution, the G-type isolates did not fall within the same cluster as the RV6 vaccine strains, except for G8. Notably, the lineage of G1 and G3 isolates differed from a previous study conducted prior to the phase III trial during 2016–2017 (Chen et al., 2021), suggesting that the lineage of the same genotype may evolve over time, even in the same regions. In our investigation, the VP6 gene of isolates was also examined. Among the 200 RV-positive samples, 150 isolates were successfully typed. The VP6 genes of 125 isolates of G9P [8], 1 isolate of G8P [8], and 1 isolate of G3P [8] were classified as belonging to the I1 genotype, in line with prevalent strains. Based on the VP6 gene, eleven isolates of G8P [8], five isolates of G3P [8], three isolates of G3P [9], two isolates of G2P [4], and one isolate of G9P [8] were classified as I2 genotype. Lastly, one isolate of G4P [6] was typed as I5 genotype. It was observed that the differences in VP7 antigenic epitopes among isolates of each genotype ranged from 3.5% to 24.1%. In isolates of G2, G3, G8, and G9, aa residues underwent changes from hydrophobic to hydrophilic in positions where transitions occurred between aspartic acid and asparagine. This suggests a potential adaptive process in the host (Mishra et al., 2020), which might lead to alterations in the immunogenicity of the vaccine (Mao et al., 2022). An aa substitution (D145 ​N) in some G3 isolates introduced a potential N-linked glycosylation site near the 7–1a epitope, known to reduce the neutralization of animal strains (Zeller et al., 2012). No mutations were observed in potential N-linked glycosylation sites of other isolates from all genotypes. While no additional disulfide bonds were noted, which implies that site alterations may not be sufficient to alter the genotype of the isolates. However, substitutions in antigenic epitopes could potentially influence the binding affinity of neutralizing antibodies and exert selective pressure on different viral strains, which needs further investigation. Nonetheless, the observed aa substitutions were unlikely to have a significant impact the efficacy of vaccine strains against prevalent strains. Antibodies against lineage I of G9 were found to neutralize not only the lineage I strains but also the lineage II and III strains at high titers (Hoshino et al., 2004). An aa substitution, such as the D96 ​N in G2, which became prevalent after the year 2000, could potentially confer a selective advantage favoring the binding of non-neutralizing antibodies at this protein site (Doan et al., 2011; Mwangi et al., 2023). Vaccine efficacy (VE) cannot be reliably predicted solely based on differences in neutralization sites between prevalent and vaccine strains; it must be substantiated through clinical trials. Given the rarity of G8 and the prevalence of G9 strains, RV6 plays a crucial role in RV prevention in China. According to the results of the phase III clinical trial (Wu et al., 2022), the VE of RV6 against RVGE was 69.21% in infants and children due to the genotypes it covers. Additionally, it demonstrated 91.36% efficacy in preventing severe RVGE and 89.21% efficacy in hospitalization due to RVGE. The VE was 100.00% for severe RVGE caused by G1, G3, and G8 genotypes. For severe RVGE caused by the most common genotype, G9, in China, the VE was 89.97%. Despite variations in the VP7 between RV6 and isolates, the clinical trial showed significant efficacy against RVGE. After re-evaluation, the VE was recalculated to be 100% for RVGE caused by G1, G4, P [6], and P [9], as well as for severe RVGE caused by G1, G3, G4, P [4], P [6], and P [9] (data not shown). Therefore, it's crucial to provide an oral hexavalent reconstituted live RV vaccine in China to prevent RV infection. The vaccine efficacy of LLR3 (Xia et al., 2020), Rotarix (Li et al., 2014), and RotaTeq (Mo et al., 2017), which have completed phase III clinical trials in China, was reported as 56.6%, 58.1%, and 74.0%, respectively, for any degree of RVGE caused by any genotype. These results were on par with the vaccine efficacy of WIBP (Wu et al., 2022). Notably, the efficacy of Rotarix and RotaTeq in China was found to be lower than in other regions. In addition, the impact of differences in VP7 epitopes between the vaccine and prevalent strains on vaccine efficacy, several factors are predicted to significantly contribute, including poor gut absorption of live-attenuated oral RV vaccine, breastfeeding, maternal antibodies, microbiota/probiotic diversity, co-infections of infectious diarrhea, and vaccine interference with other routine childhood vaccines (Folorunso and Sebolai, 2020; Desselberger, 2017; Parker et al., 2018; Ruiz-Palacios et al., 2006). Nevertheless, further monitoring is warranted to obtain a more comprehensive understanding of the long-term effect of the vaccine post-marketing. Conclusion The predominant RV genotype in China during two epidemic seasons from 2019 to 2021 was G9P [8], with other genotypes including G1P [8], G2P [4], G3P [8], G3P [9], G4P [6], and G8P [8], signifying a phylogenetically diverse array of circulating genotypes. Additionally, the rare Chinese genotypes G3P [9], G4P [6], and G8P [8] were simultaneously detected. These six genotypes exhibited variations in VP7 antigenic epitopes of isolates compared to vaccine strains. The hexavalent live human-bovine reassortant RV vaccine has demonstrated efficacy by providing comprehensive coverage against both major and rare epidemic strains in China. It is imperative to continue surveillance of RV isolates to monitor the circulating RV genotypes even after the vaccine becomes available. Data availability All the data generated during the current study are included in the manuscript. Ethics statement The study was approved by the Institutional Review Boards of Hebei, Zhejiang, Hunan, and Guangxi Provincial Center for Disease Control and Prevention and conducted in compliance with Good Clinical Practice, the Declaration of Helsinki, and local regulations in China. Written informed consents were obtained from all the participants’ parents or legal representatives. The clinical trial was registered under the number ChiCTR2100054584. Author contributions Wenqi Zou: formal analysis and writing-original draft. Qingchuan Yu: methodology and conceptualization. Qingliang Li: investigation. Yan Liu: data curation. Hong Chen: methodology. Jiamei Gao: methodology. Chen Shi: data curation. Ying Wang: supervision. Wei Chen: supervision. Xuan Bai: investigation. Biao Yang: investigation. Jiuwei Zhang: investigation. Ben Dong: investigation. Bo Ruan: investigation. Liuyifan Zhou: investigation. Gelin Xu: writing-review & editing. Zhongyu Hu: writing-review & editing. Xiaoming Yang: writing-review & editing. Conflict of interest Wenqi Zou, Qingliang Li, Hong Chen, Chen Shi, Ying Wang, Wei Chen, Xuan Bai, Biao Yang, Jiuwei Zhang, Ben Dong, Bo Ruan, Liuyifan Zhou and Gelin Xu are currently employees of Wuhan Institute of Biological Products Co., Ltd. Xiaoming Yang is currently an employee of China National Biotec Group Co., Ltd., Beijing, China. The other authors declare they have no conflicts of interest.